Physician profile
Derek Ngai
NPI 1700231859
$2,734.69
in general payments reported to CMS, 2019-2025
18 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $330 · 2021: $366 · 2022: $198 · 2023: $701 · 2024: $452 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.79 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $578.50 | 2020-2025 | Gattex, Eohilia, Vpriv |
| Abbvie INC. | $554.50 | 2019-2022 | |
| Qol Medical, LLC | $354.77 | 2019-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $322.69 | 2022-2025 | Dupixent |
| Mirum Pharmaceuticals, INC. | $191.79 | 2023-2025 | Livmarli |
| Alcresta Therapeutics, INC. | $149.11 | 2023-2025 | Relizorb |
| Janssen Biotech, INC. | $124.21 | 2022-2024 | Stelara |
| Amgen INC. | $76.56 | 2022-2023 | Amjevita, Avsola |
| Intrabio INC | $69.37 | 2025 | Aqneursa |
| Genzyme Corporation | $62.16 | 2024 | |
| Pharming Healthcare, INC. | $50.18 | 2023-2024 | Ruconest |
| Nestle Healthcare Nutrition INC. | $46.84 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $41.46 | 2024-2025 | Bylvay |
| Alexion Pharmaceuticals, INC. | $26.56 | 2019 | |
| Acadia Pharmaceuticals INC | $26.55 | 2023 | Daybue |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eton Pharmaceuticals, INC. | $22.54 | 2025 | Betaine Anhydrous, Nitisinone, Galzin |
| Travere Therapeutics, INC. | $18.65 | 2023 | Cholbam |
| Albireo Pharma, INC. | $18.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Ngai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.